Recruiting NCT05479474

Platelet Rich Plasma Testis Treatment for Infertile Men

No phase Interventional Male Infertility Nonobstructive Azoospermia Azoospermia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: Platelet rich plasma.
Who it may be relevant to: Registry conditions: Male Infertility, Nonobstructive Azoospermia, Azoospermia. Basic parameters: from 18 years · Male.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: United States
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Platelet Rich Plasma Testis

Overview

Investigate the effect of intratesticular injection of autologous platelet rich plasma (PRP) on sperm retrieval rates and IVF outcomes in infertile men who already underwent a negative sperm retrieval. Currently, there is no alternative treatment after failed TESE. Prior series suggest that intratesticular PRP injections may improve TESE outcomes. We hope to determine whether PRP is an effective treatment for this patient population.

Interventions

Biological Platelet rich plasma
Patients will undergo a blood draw (12 tsp) to prepare the PRP infusion. The use of a centrifuge and an Arteriocyte Magellan kit are necessary for the PRP preparation. After injection of local anesthesia, PRP will be injected into each testicle. * On the third month after the testicular PRP procedure, a TESE will be performed * If the procedure is successful a new IVF cycle using the sperm procured from the procedure will be done.

Primary outcome measures

sperm present [Time frame: 3 months after PRP injection]

Eligibility criteria

Inclusion criteria

Men over the age of 18 diagnosed with NOA and at least one failed TESE, negative mapping or negative biopsy

Exclusion criteria

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation: N/A
Model: Single group
Masking: Open label
Primary purpose: Treatment

Study locations

United States · 1 center

Stanford Urology Clinic — Stanford

Identifiers

NCT: NCT05479474 · 65917

Primary sources (government registries)

ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗